false
ar,be,bn,zh-CN,zh-TW,en,fr,de,hi,it,ja,ko,pt,ru,es,sw,vi
Catalog
Best of IGCS 2022 Annual Global Meeting
Antibody Drug Conjugates As an Exciting New Drug C ...
Antibody Drug Conjugates As an Exciting New Drug Class - Industry Symposium by ImmunoGen
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
Summary: The video discusses the ocular and pulmonary toxicities associated with antibody-drug conjugates (ADCs) used in the treatment of gynecological cancers. Ocular toxicities, mainly conjunctivitis and keratopathy, are relatively low grade and reversible. Regular eye exams and mitigation strategies are recommended to manage these toxicities. Pulmonary toxicity, specifically non-infectious pneumonitis, is rare but requires vigilant monitoring of respiratory symptoms and appropriate evaluation for prompt detection and management. The speaker emphasizes the importance of understanding the specific toxicities associated with each ADC and tailoring management accordingly. Overall, ADCs have shown promising benefits in gynecological cancer treatment, but careful monitoring and mitigation strategies are necessary for patient safety and treatment efficacy.<br /><br />Credits: No specific credits mentioned in the summary.
Keywords
ocular toxicities
pulmonary toxicities
antibody-drug conjugates
gynecological cancers
conjunctivitis
keratopathy
regular eye exams
mitigation strategies
pulmonary toxicity
non-infectious pneumonitis
respiratory symptoms
specific toxicities
Contact
education@igcs.org
for assistance.
×